RxDoctor Payments DataLook up a doctor →

Raul Heredia, MD

Cardiovascular Disease · Frankfort, KYNPI 1366408213

Payments from drug & device makers

$33,859in general payments, 2019–2025

Across 1,385 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$12K
  • Johnson & Johnson$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Amgen$2K
  • Novartis$2K
  • Pfizer$2K
  • plus $11K from 40 others

What the payments were for

  • Speaking & faculty fees$9,25027%
  • Food & beverage$24,35672%
  • Education$2531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,859 in reported general payments places this provider in the 85th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$173,637
Medicare patients
492
Services billed
2,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban729$817,904
FarxigaDapagliflozin Propanediol423$555,915
EntrestoSacubitril/Valsartan251$350,733
XareltoRivaroxaban246$305,804
JardianceEmpagliflozin159$195,930
Repatha SureclickEvolocumab201$163,331
MultaqDronedarone Hcl65$92,789
VascepaIcosapent Ethyl102$80,849
OzempicSemaglutide35$42,146
BrilintaTicagrelor29$27,557
Praluent PenAlirocumab31$25,317
Ranolazine ErRanolazine120$23,627
NexlizetBempedoic Acid/Ezetimibe21$23,114
Repatha SyringeEvolocumab41$22,874
VerquvoVericiguat18$22,137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,821$817,904729 claims
AstraZenecaFarxiga, Brilinta$11,909$583,473452 claims
NovartisEntresto$1,845$350,733251 claims
Johnson & JohnsonXarelto$2,707$305,804246 claims
Boehringer IngelheimJardiance$1,126$195,930159 claims
Sanofi-aventis U.S. LLCMultaq$726$92,78965 claims
Novo NordiskOzempic, Wegovy$955$56,73646 claims
Esperion Therapeutics, Inc.Nexlizet$992$23,11421 claims
MerckVerquvo$823$22,13718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Frankfort

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →